5 Einträge gefunden

1. Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment

   1. Leutz, A
   2. Pinter, A
   3. Thaçi, D
   4. Augustin, M
   5. Schuster, C
   6. Fotiou, K
   7. Hundemer, H P

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
2. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment

   1. Reich, K
   2. Augustin, M
   3. Thaçi, D
   4. Pinter, A
   5. Leutz, A
   6. Henneges, C
   7. Schneider, E

   2020 - Forschungsinformationssystem des UKE
3. Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management

   1. Augustin, M
   2. Langenbruch, A
   3. Gutknecht, M
   4. Reich, K
   5. Körber, A
   6. Maaßen, D
   7. Mrowietz, U

   2018 - Forschungsinformationssystem des UKE
4. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic Treatments: results from the randomized controlled PRIME trial

   1. Sticherling, M
   2. Mrowietz, U
   3. Augustin, M
   4. Thaçi, D
   5. Melzer, N
   6. Hentschke, C
   7. Kneidl, J

   2017 - Forschungsinformationssystem des UKE
5. The German National Program on Psoriasis Health Care 2005-2015: Results and Experiences

   1. Augustin, M
   2. Eissing, L
   3. Langenbruch, A
   4. Enk, A
   5. Luger, T
   6. Maaßen, D
   7. Mrowietz, U

   2016 - Forschungsinformationssystem des UKE